Abstract
A complex form of aggression, commonly expanded as ‘aggressive challenging behaviour’, is reported in one in four adults with intellectual disability and is often treated with antipsychotics, mood stabilizers and antidepressants. Psychological treatments, including anger and behavioural management, person-centred planning and manipulation of the environment (nidotherapy), have also been used when available but to a lesser extent. In this article, the evidence for efficacy for each intervention is examined, with data from randomized controlled trials given primacy. Very little evidence, based on limited data, can be found for the interventions of anger and behavioural management and also for the atypical antipsychotic drug, risperidone; the data available on these interventions come primarily from studies conducted in children in whom the behaviour is part of the autistic spectrum. Antipsychotic drugs, particularly the atypical group, have been the most commonly used interventions in recent years, but a recent independent randomized trial showed no benefits for either risperidone or haloperidol compared with placebo, with some evidence of a better response to placebo than either active drug in the reduction of aggression.
In the light of this uncertainty, the clinician must return to the task of collecting a careful history and mental state examination, including awareness of the setting in which the behaviour is shown, which will help with diagnosis and appropriate intervention. The choice of intervention should not be a casual one and is not likely to be chosen well if the clinician relies only on standard guidelines.
The paucity of randomized trial evidence is preventing progress in the treatment of persistent aggressive behaviour. On present evidence, the use of drug treatment should be much more sparing and reserved for those patients who are putting themselves and others at particular risk as a consequence of their behaviour; such treatment should be regarded as temporary and as adjunctive to other forms of management. There is an urgent need for larger, randomized studies of psychological interventions, which at present appear to have a higher benefit-risk ratio than drug treatment but that also have a poor evidence base. More care should be taken to avoid the term ‘aggressive challenging behaviour’ being used as a portmanteau diagnostic pseudonym when it merely represents a diverse oppositional repertoire of many aetiologies.
Similar content being viewed by others
References
Tyrer P, Tyrer S. Other treatments for persistent disturbances of behaviour. In: Tyrer P, Silk K, editors. Cambridge handbook of essential treatments in psychiatry. Cambridge: Cambridge University Press, 2008: 682–9
Strydom A, Livingston G, King M, et al. Prevalence of dementia in intellectual disability using different diagnostic criteria. Br J Psychiatry 2007; 191: 150–7
Emerson E, McGill P, Mansell J. Severe learning disabilities and challenging behaviours: designing high quality services. London: Chapman and Hall, 1994
Iwata BA, Dorsey MF, Slifer KJ, et al. Toward a functional analysis of self injury. Anal Intervent Devel Disabil 1982; 2: 1–20
O’Neill RE, Horner RH, Albin RW, et al. Functional analysis of problem behavior: a practical assessment guide. 2nd ed. Pacific Grove (CA): Brooks/Cole, 1997
Brylewski J, Duggan L. Antipsychotic medication for challenging behaviour in people with intellectual disability: a systematic review of randomised controlled trials. Cochrane Database Syst Rev 2007; (3): CD000377
Cooper SA, Smiley E, Morrison J, et al. Mental ill health in adults with intellectual disabilities: prevalence and associated factors. Br J Psychiatry 2007; 190: 27–35
Jones S, Cooper SA, Smiley E, et al. Prevalence of, and factors associated with, problem behaviors in adults with intellectual disabilities. J Nerv Ment Dis 2008; 196: 678–86
Tenneij NH, Koot HM. Incidence, types and characteristics of aggressive behaviour in treatment facilities for adults with mild intellectual disability and severe challenging behaviour. J Intellect Disabil Res 2008; 52: 114–24
Smiley E, Cooper S-A, Finlayson J, et al. Incidence and predictors of mental ill-health in adults with intellectual disabilities. Br J Psychiatry 2007; 191: 313–9
Emerson E, Hatton C. Mental health of children and adolescents with intellectual disabilities in Britain. Br J Psychiatry 2007; 191: 493–9
Emerson E, Kiernan C, Alborz A, et al. The prevalence of challenging behaviors: a total population study. Res Dev Dis 2001; 22: 77–93
Smith S, Branford D, Collacott DA, et al. Prevalence and cluster typology of maladaptive behaviors in a geographically defined population of adults with learning disabilities. Br J Psychiatry 1996; 169: 219–27
Alexander R, Cooray S. Diagnosis of personality disorders in learning disability. Br J Psychiatry 2003; 182(44 Suppl.): s28–31
Kiernan C, Reeves D, Alborz A. The use of anti-psychotic drugs with adults with learning disabilities and challenging behaviour. J Intellect Disabil Res 1995; 39: 263–74
Branford D. A study of the prescribing for people with learning disabilities living in the community and in National Health Service care. J Intellect Disabil Res 1994; 38: 577–86
Linaker OM. Frequency and determinants for psychotropic drug use in an institution for the mentally retarded. Br J Psychiatry 1990; 156: 525–30
Thalayasingam S, Alexander RT, Singh I. The use of clozapine in adults with intellectual disability. J Intellect Disabil Res 2004; 48: 572–9
Haessler F, Glaser T, Beneke LJ, et al. Zuclopenthixol in aggressive challenging behaviour in learning disability: discontinuation study. Br J Psychiatry 2007; 190: 447–8
Janowsky DS, Barnhill LJ, Davis JM. Olanzapine for self-injurious, aggressive, and disruptive behaviors in intellectually disabled adults: a retrospective, open-label, naturalistic trial. J Clin Psychiatry 2003; 64: 1258–65
Van den Borre R, Vermote R, Buttiens M, et al. Risperidone as add-on therapy in behavioral disturbances in mental-retardation: a double-blind placebo-controlled cross-over study. Acta Psychiat Scand 1993; 87: 167–71
Hellings JA, Zarcone JR, Reese RM, et al. A crossover study of risperidone in children adolescents and adults with mental retardation. J Autism and Dev Disord 2006; 36: 401–11
Gagiano C, Read S, Thorpe L, et al. Short and long-term efficacy and safety of risperidone in adults with disruptive behaviour disorders. Psychopharmacol (Berl) 2005; 179: 629–36
Tyrer P, Oliver-Africano PC, Ahmed Z, et al. Risperidone, haloperidol and placebo in the treatment of aggressive challenging behaviour in patients with intellectual disability: a randomised controlled trial. Lancet 2008; 371: 57–63
McDougle CJ, Naylor ST, Cohen DJ, et al. A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder. Arch Gen Psychiatry 1996; 53: 1001–8
Janowsky DS, Shetty M, Barnhill LJ, et al. Serotonergic antidepressant effects on aggressive, self-injurious and destructive/disruptive behaviours in intellectually disabled adults: a retrospective, open-label, naturalistic trial. Int J Neuropsychopharmacol 2005; 8: 37–48
Branford D, Bhaumik S, Nai K. Selective serotonin reuptake inhibitors for the treatment of perseverative and maladaptive behaviours of people with intellectual disability. J Intellect Disabil Res 1998; 42: 301–6
Tyrer SP, Walsh A, Edwards DE, et al. Factors associated with a good response to lithium in aggressive mentally handicapped subjects. Progr Neuropsychopharmacol Biol Psychiatry 1984; 8: 751–5
Craft M, Ismail IA, Krisnamurti D, et al. Lithium in the treatment of aggression in mentally handicapped patients: a double-blind trial. Br J Psychiatry 1987; 150: 685–9
Taylor JL, Novaco RW, Gillmer B, et al. Cognitive-behavioural treatment of anger intensity among offenders with intellectual disabilities. J Appl Res Intellect Disabil 2002; 15: 151–65
Willner P, Jones J, Tams R, et al. A randomised controlled trial of the efficacy of a cognitive-behavioural anger management group for adults with learning disabilities. J Appl Res Intellect Disabil 2002; 15: 224–35
UK Clinical Research Network. UKCRN ID 7089 [online]. Available from URL: http://public.ukcrn.org.uk/search/StudyDetail.aspx?StudyID=7089 [Accessed 2009 Jul 11]
Petry N. Contingency management treatments: a uniquely American approach, or perhaps even better suited for European drug abuse treatment? Br J Psychiatry 2006; 189: 97–8
LaGrow SJ, Repp AC. Stereotypic responding: a review of intervention research. Am J Mental Defic Res 1984; 88: 595–609
Scotti JR, Evans IM, Meyer LH, et al. A meta-analysis of intervention research with problem behaviour: treatment validity and standards of practice. Am J Ment Retard 1991; 93: 233–56
Peck Peterson SM, Caniglia C, Royster AJ, et al. Blending functional communication training and choice making to improve task engagement and decrease problem behaviour. Educ Psychol 2005; 25: 257–74
Shogren KA, Faggella-Luby M, Bae SJ, et al. The effect of choice-making as an intervention for problem behaviour: a meta-analysis. J Pos Behav Interventions 2004; 6: 228–37
Hassiotis A, Rowbotham D, Canagasaby A, et al. A randomized, single-blind, controlled trial of a specialist behavior therapy team for challenging behavior in adults with intellectual disabilities. Am J Psychiatry. In press
Haddock K, Jones RS. Practitioner consensus in the use of cognitive behaviour therapy for individuals with a learning disability. J Intellect Disabil 2006; 10: 221–30
Browder DM, Bambara LM, Belfiore PJ. Using a person-centred approach in community-based institutions for adults with developmental disabilities. J Behav Educ 1997; 7: 519–28
Hammel J. Technology and the environment: supportive resource or barrier for people with developmental disabilities? Nurs Clin North Am 2003; 38: 331–49
Tyrer P, Bajaj P. Nidotherapy: making the environment do the therapeutic work. Adv Psychiatric Treat 2005; 11: 232–8
Tyrer P, Kramo K. Nidotherapy in practice. J Ment Health 2007; 16: 117–31
Merrick J, Cahana C, Lotan M, et al. Snoezelen or controlled multisensory stimulation: treatment aspects from Israel. Scient World J 2004; 4: 307–14
Chung JC, Lai CK, Chung PM, et al. Snoezelen for dementia. Cochrane Database Syst Rev 2002; (4): CD003152
Savarithmu D, Bunnell T. The effects of music on clients with learning disabilities: a literature review. Complement Ther Nurs Midwifery 2002 Aug 8; 3: 160–5
Oliver PC, Piachaud J, Done J, et al. Difficulties in conducting a randomised controlled trial of health service interventions in intellectual disability: implications for evidence-based practice. J Intellect Disabil Res 2002; 46: 340–5
Willner P. The effectiveness of psychotherapeutic interventions for people with learning disabilities: a critical overview. J Intellect Disabil Res 2005; 49: 73–85
Miller DD, Caroff SN, Davis SM, et al. Extrapyramidal side effects of antipsychotics in a randomized trial: findings from the CATIE Schizophrenia Trial. Br J Psychiatry 2008; 193: 279–88
Brylewski J, Duggan L. Antipsychotic medication for challenging behaviour in people with intellectual disability: a systematic review of randomized controlled trials. J Intellect Disabil Res 1999; 43: 360–71
La Malfa G, Lassi S, Bertelli M, et al. Reviewing the use of antipsychotic drugs in people with intellectual disability. Hum Psychopharmacol 2006; 21: 73–89
Ahmed Z, Fraser W, Kerr MP, et al. Reducing antipsychotic medication in people with a learning disability. Br J Psychiatry 2000; 176: 42–6
Bekelman JE, Li Y, Gross PC. Scope and impact of financial conflict of interest in biomedical research: a systematic review. JAMA 2003; 289: 454–65
Tungaraza T, Poole R. Influence of drug company authorship and sponsorship on drug trial outcomes. Br J Psychiatry 2007; 191: 82–3
Buitelaar JK, Van der Gaag RJ, Cohen-Kettenis P, et al. A randomized controlled trial of risperidone in the treatment of aggression in hospitalized adolescents with subaverage cognitive abilities. J Clin Psychiatry 2001; 62: 239–48
Aman MG, Singh NN, Stewart AW, et al. The Aberrant Behavior Checklist: a behavior rating scale for the assessment of treatment effects. Am J Ment Defic 1985; 89: 485–91
Aman MG, De Smedt G, Derivan A, et al. Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviours in children with subaverage intelligence. Am J Psychiatry 2002; 159: 1337–46
McDougle CJ, Scahill L, Aman MG, et al. Risperidone for the core symptom domains of autism: results from the study by the autism network of the research units on pediatric psychopharmacology. Am J Psychiatry 2005; 162: 1142–8
McCracken JT, McGough J, Shah B, et al. Risperidone in children with autism and serious behavioural problems. New Engl J Med 2002; 347: 314–20
McDougle CJ, Stigler KA, Erickson CA, et al. A typical antipsychotics in children and adolescents with autistic and other pervasive developmental disorders. J Clin Psychiatry 2008; 69 Suppl. 4: 15–20
Janowsky DS, Kraus JE, Barnhill LJ, et al. Effects of topiramate on aggressive, self-injurious, and disruptive/ destructive behaviors in the intellectually disabled: an open-label retrospective study. J Clin Psychopharmacol 2003; 23: 500–4
Stolker JJ, Heerdink ER, Leufkens HG, et al. Determinants of multiple psychotropic use in patients with mild intellectual disabilities or borderline intellectual function and psychiatric or behavioural disorders. Gen Hosp Psychiatry 2001; 23: 345–9
Rangecroft MEH, Tyrer SP, Berney TP. The use of seclusion and emergency medication in a hospital for people with learning disability. Br J Psychiatry 1997; 170: 273–7
Fisher WW, Adelinis JD, Volkert VM, et al. Assessing preferences for positive and negative reinforcement during treatment of destructive behaviour with functional communication training. Res Development Disabil 2005; 26: 153–68
Tyrer P, Sensky T, Mitchard S. The principles of nidotherapy in the treatment of persistent mental and personality disorders. Psychother Psychosom 2003; 72: 350–6
Stirling C, McHugh A. Developing a non-aversive intervention strategy in the management of aggression and violence for people with learning disabilities using natural therapeutic holding. J Adv Nurs 1998; 27: 503–9
Hassiotis A, Hall I. Behavioural and cognitive-behavioural interventions for outwardly-directed aggressive behaviour in people with learning disabilities. Cochrane Database Syst Rev 2004 Oct 18; (4): CD003406
Hassiotis AA, Hall I. Behavioural and cognitive-behavioural interventions for outwardly-directed aggressive behaviour in people with learning disabilities. Cochrane Database Syst Rev 2008 Jul 16; (3): CD0034062008
Tyrer P, Oliver-Africano P, Romeo R, et al. Neuroleptics in the treatment of aggressive challenging behaviour for people with intellectual disabilities: a randomised controlled trial (NACHBID trial). Health Technol Assess 2009; 13(21): iii–iv, ix-xi, 1-54
Morgan VA, Leonard H, Bourke J, et al. Intellectual disability co-occurring with schizophrenia and other psychiatric illness: population-based study. Br J Psychiatry 2008; 193: 364–72
Acknowledgements
The authors were supported by the National Coordinating Centre for Health Technology Assessment (NCCHTA), Southampton, UK, in their funding of the NACHBID (Neuroleptics in Adults with Aggressive Challenging Behaviour and Intellectual Disability) trial mentioned in this review. The views expressed are those of the authors alone. We thank Anna Maratos, Stephen Tyrer, Adrienne Regan and Freya Tyrer for providing data and comments in the preparation of this paper. Dr Oliver-Africano has acted as a consultant for Maitland in analyzing the resource use of individuals with a developmental disability in Ontario for the Client Ministry of Community and Social Services, Ontario, Canada. Drs Tyrer and Murphy have no conflicts of interest that are directly relevant to the content of this review.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Oliver-Africano, P., Murphy, D. & Tyrer, P. Aggressive Behaviour in Adults with Intellectual Disability. CNS Drugs 23, 903–913 (2009). https://doi.org/10.2165/11310930-000000000-00000
Published:
Issue Date:
DOI: https://doi.org/10.2165/11310930-000000000-00000